What’s the current price of Alectinib in the United States?
Alectinib (brand name Xalkori) typically costs between $1,500 and $2,200 per month at the pharmacy. The exact figure depends on the pharmacy’s negotiated fee, the patient’s insurance coverage, and any applicable discounts.
How does insurance affect what I pay?
Most U.S. insurers apply a tiered cost structure. If Alectinib is the preferred drug in its class, copays can be as low as a few dollars a day. Outside the preferred tier, patients might face 20–30 % of the wholesale price, or higher, depending on their plan.
Are there patient‑assistance programs?
The manufacturer offers a program that can lower the net price for uninsured patients or those with high out‑of‑pocket costs. Eligibility is based on income, insurance status, and prescription quantity.
What is the price in Canada, Europe, and other markets?
In Canada, the average retail price is roughly CAD 1,400–1,800 per month. Prices in the EU vary widely: for example, the United Kingdom lists Alectinib at about £1,200 per month, while Germany’s list price is around €1,800 per month. These figures are before insurance or national formulary negotiations.
How does Alectinib’s cost compare to other ALK inhibitors?
Other ALK inhibitors—such as crizotinib, ceritinib, and lorlatinib—generally trade off between $1,200 and $2,000 per month in the U.S. Alectinib sits on the higher end of that spectrum, reflecting its newer approval and extended efficacy.
What drives the price of Alectinib?
Key drivers include the drug’s patent protection, limited competition, research and development investment, and the cost of clinical trials that demonstrated its benefit in ALK‑positive non‑small‑cell lung cancer.
Can pharmacists or pharmacies offer rebates or discounts?
Many pharmacies participate in manufacturer rebate programs or discount card plans that can reduce the patient’s out‑of‑pocket cost by 10–20 %. The actual discount varies by pharmacy and the patient’s insurance plan.
How does the manufacturer set the price?
The company uses a cost‑plus model that incorporates research expenses, production costs, and market comparators. They also consider the willingness to pay of insurers and national payers, adjusting the list price to secure formulary placement and reimbursement.
These points cover the common questions that arise when patients and payers look up Alectinib’s price.